IL-PRICEFX
18.1.2022 15:32:10 CET | Business Wire | Press release
Pricefx , the global leader in cloud pricing software, today announced it closed the best quarter in company history due to strong customer and partner traction in 2021. With 26 deals closed in Q4 2021 and 34 new enterprise customers added in 2021, the company ended the year with 45% year-over-year annual recurring revenue (ARR) growth. Key new customers include American Tire Distributors, Extreme Networks, KeHe Distributors and Tamko Building Products. Additionally, Pricefx recorded 95% customer retention and closed 23 customer expansion deals.
In 2021, Pricefx increased revenue growth with SAP by 140% over 2020. The Advantage Pricefx partner program continued to drive significant return on investment in 2021 with at least one partner engaged on 70% of new customers signed through co-selling, influencing, and/or implementing the Pricefx solution. Several global system integrators, such as the KPMG German member firm, joined Pricefx’s ecosystem broadening the company’s reach and deepening its pricing expertise.
To support this growth, the company expanded its ranks by 11% in 2021, adding several key hires during the year. Ronak Sheth joined the company in May as President and Chief Revenue Officer. Toby Davidson was named Chief Product and Technology Officer in January, leading the development of several new product features throughout the year. In January, Pricefx partnered with Bain & Company to launch PricefxPlasma™ , the industry’s first big data powered benchmarking platform. To address the increased demand for AI-driven revenue growth, Pricefx introduced the industry’s first AI-powered market simulation solution in April. Pricefx also simplified its product offering around three core packages Plan , Price and Profit , showcased in the company’s recently updated website.
Pricefx also brought Doug Fuehne on board as Senior Vice President to lead the newly formed Pricefx Impact team. With more than two decades of experience in pricing and software, Fuehne joined Pricefx from Amazon where he was the Global Practice Lead, Manufacturing & Supply Chain for Amazon Web Services (AWS) and led the creation of AWS’ digital supply chain transformation methodology. Prior to that, he was the Head of Customer Success for Commercial Industries at Amazon Business where he led the ProServe implementation team for Amazon’s B2B distribution division. The Impact team works across the entire customer lifecycle to help customers identify the best solutions specific to their industry and strategic goals, understand and measure the value delivered, and grow the value obtained from Pricefx over time.
“Supply chain issues, pricing fluctuations and inflationary pressures across nearly every industry forced companies to find ways to adjust to a volatile market,” said Sheth. “Pricefx was able to help companies navigate these challenges and maintain its leadership position in the market surge for price optimization. Our industry-leading pricing solutions, ability to create a customized plan for customers to achieve profitable growth in record time, and relentless focus on customer satisfaction has led to a blockbuster year for the company, including new customer acquisitions and continued expansion into existing accounts.”
Pricefx was named a Chicago Best Mid-Sized Companies to Work For by Built In for the second year in a row. The company was also an SAP® Pinnacle Award finalist for the second year in a row; this year in the Partner of the Year – Endorsed Apps category. Continuing the back-to-back streak, Pricefx was named Product of the Year in the 2021 Sales and Marketing Technology Awards program, also known as The Sammys. The company was also awarded the Gold GLOBEE® for Configure Price Quote (CPQ) in the 2021 IT World Awards® and honored with a Silver Stevie® Award in the manufacturing business technology category of the 2021 American Business Awards®. The Global Business Tech Awards named Pricefx to its shortlist for Best SaaS Company of the Year and the SaaS Awards shortlisted Pricefx in two categories.
Follow Pricefx
LinkedIn: https://www.linkedin.com/company/price-f-x-/
Twitter: https://twitter.com/price_fx
About Pricefx
Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Based on cloud-native architecture, Pricefx delivers a complete price optimization and management platform that provides the industry’s fastest time-to-value and lowest total cost of ownership. Its innovative solution works for B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. For enterprises facing pricing challenges, Pricefx is the cloud pricing optimization, management, and CPQ platform to dynamically Plan, Price and Profit.
For more information, please visit www.pricefx.com .
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices. All other product and service names mentioned are the trademarks of their respective companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005430/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
